➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

Express Scripts
Johnson and Johnson
Boehringer Ingelheim
Baxter
Colorcon
McKinsey

Last Updated: May 14, 2021

DrugPatentWatch Database Preview

Details for Patent: 10,821,108

➤ Get the DrugPatentWatch Daily Briefing
» See Plans and Pricing

« Back to Dashboard

Which drugs does patent 10,821,108 protect, and when does it expire?

Patent 10,821,108 protects UPTRAVI and is included in one NDA.

This patent has twenty-one patent family members in nineteen countries.

Summary for Patent: 10,821,108
Title:Pharmaceutical composition containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide
Abstract: A stabilized solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide is provided, namely, a solid preparation containing 2-{4-[N-(5,6-diphenylpyrazin-2-yl)-N-isopropylamino]butyloxy}-N-(methylsu- lfonyl)acetamide and D-mannitol having a specific surface area of 1.0 m.sup.2/g or less.
Inventor(s): Furuta; Shouji (Kyoto, JP), Mukai; Hironori (Kyoto, JP)
Assignee: NIPPON SHINYAKU CO., LTD. (Kyoto, JP)
Application Number:15/777,711
Patent Claim Types:
see list of patent claims
Use; Composition; Compound; Dosage form;

Drugs Protected by US Patent 10,821,108

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Actelion UPTRAVI selexipag TABLET;ORAL 207947-001 Dec 21, 2015 RX Yes No   Get Started for $10   Get Started for $10 Y   Get Started for $10
Actelion UPTRAVI selexipag TABLET;ORAL 207947-002 Dec 21, 2015 RX Yes Yes   Get Started for $10   Get Started for $10 Y   Get Started for $10
Actelion UPTRAVI selexipag TABLET;ORAL 207947-003 Dec 21, 2015 RX Yes No   Get Started for $10   Get Started for $10 Y   Get Started for $10
Actelion UPTRAVI selexipag TABLET;ORAL 207947-004 Dec 21, 2015 RX Yes No   Get Started for $10   Get Started for $10 Y   Get Started for $10
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

Foreign Priority and PCT Information for Patent: 10,821,108

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan2015-236034Dec 2, 2015
PCT Information
PCT FiledDecember 01, 2016PCT Application Number:PCT/JP2016/085822
PCT Publication Date:June 15, 2017PCT Publication Number: WO2017/098998

International Family Members for US Patent 10,821,108

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Australia 2016366073   Get Started for $10
Brazil 112018009534   Get Started for $10
Canada 3005169   Get Started for $10
Chile 2018001464   Get Started for $10
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Moodys
Express Scripts
Merck
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.